Results for this period
Interim period (second quarter)2024年1月1日~2024年6月30日ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
為替の影響、関連する電子機器の生産が回復基調にあること、先端パッケージ基板向け製品需要の拡大、薬品の生産数量の増加、グローバル生産戦略における生産効率改善。
No applicable matters ("There are no applicable matters")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年1月1日~2024年6月30日 |
| Net Sales | ¥8,882 million (YoY +43.3%) |
| Operating profit | ¥2,362 million (YoY +181.8%) |
| Ordinary income | ¥2,641 million (YoY +163.3%) |
| Profit attributable to owners of the parent | ¥1,890 million (YoY +75.7%) |
| Net income per share | 100.97円 |
| Operating Margin | 26.6% |
| Equity ratio | End of the current fiscal period 85.7% / End of previous period 86.4% |
| Total assets | ¥31,410 million |
| Net assets | ¥26,932 million |
| Cash flows from operating activities | ¥1,989,907 thousand |
| Cash flows from investing activities | ¥-79,993 thousand |
| Cash flows from financing activities | ¥-483,245 thousand |
| Cash and cash equivalents at end of period | ¥8,358,888 thousand |
| Full-year earnings forecast | Net Sales ¥18,500 million (YoY +32.0%) / Operating profit ¥4,900 million (YoY +96.6%) / Ordinary income ¥5,200 million (YoY +93.8%) / Net income ¥3,600 million (YoY +56.2%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥18,500 million / Operating profit Not disclosed → ¥4,900 million / Ordinary income Not disclosed → ¥5,200 million / Net income Not disclosed → ¥3,600 million |
| Annual Dividend Forecast | ¥45 → ¥45(0.0%) |
| Segment revenue | Japan ¥3,545,785 thousand (YoY +46.3%), Taiwan ¥1,674,027 thousand (YoY +38.9%), Hong Kong ¥1,066,483 thousand (YoY +48.0%), China ¥1,702,971 thousand (YoY +50.9%), Thailand ¥360,306 thousand (YoY +27.0%), Europe ¥532,920 thousand (YoY +22.1%) |
| Segment profit | Japan ¥1,703,168 thousand (YoY +594.2%), Taiwan ¥248,322 thousand (YoY +153.1%), Hong Kong ¥221,104 thousand (YoY +140.1%), China ¥306,219 thousand (YoY +459.8%), Thailand ¥33,029 thousand (YoY +1,172.0%), Europe ¥24,085 thousand (YoY +50.9%) |
| Regional sales | ¥3,545,785 thousand (YoY +46.3%), ¥1,674,027 thousand (YoY +38.9%), ¥1,066,483 thousand (YoY +48.0%), ¥1,702,971 thousand (YoY +50.9%), ¥360,306 thousand (YoY +27.0%), ¥532,920 thousand (YoY +22.1%) |
| Depreciation and amortization | ¥391,573 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥6,700 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥10,824 thousand |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 20,071,093 |
| Treasury Shares at Period-End | 1,346,241 |
| Factors Behind Changes in Business Performance | 為替の影響、関連する電子機器の生産が回復基調にあること、先端パッケージ基板向け製品需要の拡大、薬品の生産数量の増加、グローバル生産戦略における生産効率改善。 |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.為替の影響、関連する電子機器の生産回復、先端パッケージ基板向け製品需要の拡大、薬品の生産数量の増加、グローバル生産戦略における生産効率改善など。